US3691016A
(en)
|
1970-04-17 |
1972-09-12 |
Monsanto Co |
Process for the preparation of insoluble enzymes
|
CA1023287A
(en)
|
1972-12-08 |
1977-12-27 |
Boehringer Mannheim G.M.B.H. |
Process for the preparation of carrier-bound proteins
|
US4195128A
(en)
|
1976-05-03 |
1980-03-25 |
Bayer Aktiengesellschaft |
Polymeric carrier bound ligands
|
US4330440A
(en)
|
1977-02-08 |
1982-05-18 |
Development Finance Corporation Of New Zealand |
Activated matrix and method of activation
|
CA1093991A
(en)
|
1977-02-17 |
1981-01-20 |
Hideo Hirohara |
Enzyme immobilization with pullulan gel
|
US4229537A
(en)
|
1978-02-09 |
1980-10-21 |
New York University |
Preparation of trichloro-s-triazine activated supports for coupling ligands
|
US4543439A
(en)
|
1982-12-13 |
1985-09-24 |
Massachusetts Institute Of Technology |
Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
|
IL71691A
(en)
|
1984-04-27 |
1991-04-15 |
Yeda Res & Dev |
Production of interferon-ypsilon
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
US5474982A
(en)
|
1986-08-13 |
1995-12-12 |
Zymogenetics, Inc. |
PDGF analogs and methods of use
|
US5322691A
(en)
|
1986-10-02 |
1994-06-21 |
Sohrab Darougar |
Ocular insert with anchoring protrusions
|
AU622105B2
(en)
|
1987-03-11 |
1992-04-02 |
Austin Research Institute, The |
Immunoglobulin conjugates
|
US5750375A
(en)
|
1988-01-22 |
1998-05-12 |
Zymogenetics, Inc. |
Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
|
US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
EP0721983A1
(en)
|
1988-01-22 |
1996-07-17 |
ZymoGenetics, Inc. |
Methods of producing biologically active peptide dimers
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
WO1990014425A1
(en)
|
1989-05-22 |
1990-11-29 |
Zymogenetics, Inc. |
PDGF α-RECEPTOR
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
US5670488A
(en)
|
1992-12-03 |
1997-09-23 |
Genzyme Corporation |
Adenovirus vector for gene therapy
|
AU7906691A
(en)
|
1990-05-23 |
1991-12-10 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
Adeno-associated virus (aav)-based eucaryotic vectors
|
US6011020A
(en)
|
1990-06-11 |
2000-01-04 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligand complexes
|
US6147204A
(en)
|
1990-06-11 |
2000-11-14 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligand complexes
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
DK0546073T3
(da)
|
1990-08-29 |
1998-02-02 |
Genpharm Int |
Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5328688A
(en)
|
1990-09-10 |
1994-07-12 |
Arch Development Corporation |
Recombinant herpes simplex viruses vaccines and methods
|
US5849571A
(en)
|
1990-10-10 |
1998-12-15 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Latency active herpes virus promoters and their use
|
GB9101645D0
(en)
|
1991-01-25 |
1991-03-06 |
British Bio Technology |
Compounds
|
EP0584082B1
(en)
|
1991-01-31 |
2000-05-31 |
Cor Therapeutics, Inc. |
Domains of extracellular region of human platelet derived growth factor receptor polypeptides
|
US5840867A
(en)
|
1991-02-21 |
1998-11-24 |
Gilead Sciences, Inc. |
Aptamer analogs specific for biomolecules
|
DK0536350T3
(da)
|
1991-02-22 |
2002-09-02 |
American Cyanamid Co |
Identifikation af et nyt humant receptor-tyrosinkinase-gen
|
US5231001A
(en)
|
1991-03-14 |
1993-07-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
|
US5270458A
(en)
|
1991-04-02 |
1993-12-14 |
The Trustees Of Princeton University |
Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
|
US5367057A
(en)
|
1991-04-02 |
1994-11-22 |
The Trustees Of Princeton University |
Tyrosine kinase receptor flk-2 and fragments thereof
|
US5185438A
(en)
|
1991-04-02 |
1993-02-09 |
The Trustees Of Princeton University |
Nucleic acids encoding hencatoporetic stem cell receptor flk-2
|
US5582981A
(en)
|
1991-08-14 |
1996-12-10 |
Gilead Sciences, Inc. |
Method for identifying an oligonucleotide aptamer specific for a target
|
CA2078539C
(en)
|
1991-09-18 |
2005-08-02 |
Kenya Shitara |
Process for producing humanized chimera antibody
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
EP0620826A1
(en)
|
1992-01-09 |
1994-10-26 |
Helsinki University Holding, Ltd. |
Tie, a novel endothelial cell receptor tyrosine kinase
|
US6331302B1
(en)
|
1992-01-22 |
2001-12-18 |
Genentech, Inc. |
Protein tyrosine kinase agonist antibodies
|
AU3482493A
(en)
|
1992-01-22 |
1993-09-01 |
New England Deaconess Hospital |
Novel protein tyrosine kinases
|
US5635177A
(en)
|
1992-01-22 |
1997-06-03 |
Genentech, Inc. |
Protein tyrosine kinase agonist antibodies
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US5776427A
(en)
|
1992-03-05 |
1998-07-07 |
Board Of Regents, The University Of Texas System |
Methods for targeting the vasculature of solid tumors
|
US5234784A
(en)
|
1992-04-01 |
1993-08-10 |
Eastman Kodak Company |
Method of making a projection viewable transparency comprising an electrostatographic toner image
|
US5879934A
(en)
|
1992-07-31 |
1999-03-09 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Herpes simplex virus strains for gene transfer
|
US6107046A
(en)
|
1992-10-09 |
2000-08-22 |
Orion Corporation |
Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
|
US5776755A
(en)
|
1992-10-09 |
1998-07-07 |
Helsinki University Licensing, Ltd. |
FLT4, a receptor tyrosine kinase
|
US6824777B1
(en)
|
1992-10-09 |
2004-11-30 |
Licentia Ltd. |
Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
DE69233803D1
(de)
|
1992-10-28 |
2011-03-31 |
Genentech Inc |
Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
|
US5763441A
(en)
|
1992-11-13 |
1998-06-09 |
Sugen, Inc. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
US5712395A
(en)
|
1992-11-13 |
1998-01-27 |
Yissum Research Development Corp. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
US5661033A
(en)
|
1992-11-25 |
1997-08-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Gene transfer using herpes virus vectors as a tool for neuroprotection
|
US5631237A
(en)
|
1992-12-22 |
1997-05-20 |
Dzau; Victor J. |
Method for producing in vivo delivery of therapeutic agents via liposomes
|
DE4311651A1
(de)
|
1993-04-08 |
1994-10-13 |
Boehringer Ingelheim Int |
Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
|
US5834441A
(en)
|
1993-09-13 |
1998-11-10 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral (AAV) liposomes and methods related thereto
|
DE69433592T2
(de)
|
1993-11-09 |
2005-02-10 |
Targeted Genetics Corp., Seattle |
Die erzielung hoher titer des rekombinanten aav-vektors
|
US5443505A
(en)
|
1993-11-15 |
1995-08-22 |
Oculex Pharmaceuticals, Inc. |
Biocompatible ocular implants
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
FR2716682B1
(fr)
|
1994-01-28 |
1996-04-26 |
Centre Nat Rech Scient |
Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
|
US6448077B1
(en)
|
1994-02-10 |
2002-09-10 |
Imclone Systems, Inc. |
Chimeric and humanized monoclonal antibodies specific to VEGF receptors
|
US6040157A
(en)
|
1994-03-08 |
2000-03-21 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US5932540A
(en)
|
1994-03-08 |
1999-08-03 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US6608182B1
(en)
|
1994-03-08 |
2003-08-19 |
Human Genome Sciences, Inc. |
Human vascular endothelial growth factor 2
|
DE69434538T2
(de)
|
1994-03-08 |
2006-08-10 |
Human Genome Sciences, Inc. |
Vaskulärer endothelialer Wachstumsfaktor 2
|
US6734285B2
(en)
|
1994-03-08 |
2004-05-11 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2 proteins and compositions
|
GB9410534D0
(en)
|
1994-05-26 |
1994-07-13 |
Lynxvale Ltd |
Improvements in or relating to growth factor inhibitors
|
ES2263152T3
(es)
|
1994-06-09 |
2006-12-01 |
Licentia Oy |
Anticuerpo monoclonal contra el receptor flt4 tirosina quinasa y su uso en diagnostico y terapia.
|
US6204059B1
(en)
|
1994-06-30 |
2001-03-20 |
University Of Pittsburgh |
AAV capsid vehicles for molecular transfer
|
US5763733A
(en)
|
1994-10-13 |
1998-06-09 |
Enzon, Inc. |
Antigen-binding fusion proteins
|
US5856152A
(en)
|
1994-10-28 |
1999-01-05 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV vector and methods of use therefor
|
US6130071A
(en)
|
1997-02-05 |
2000-10-10 |
Helsinki University Licensing, Ltd. |
Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
|
US6403088B1
(en)
|
1995-08-01 |
2002-06-11 |
Helsinki University Licensing, Ltd. |
Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
|
US6645933B1
(en)
|
1995-08-01 |
2003-11-11 |
Helsinki University Licensing Ltd. Oy |
Receptor ligand VEGF-C
|
US6221839B1
(en)
|
1994-11-14 |
2001-04-24 |
Helsinki University Licensing Ltd. Oy |
FIt4 ligand and methods of use
|
WO1998033917A1
(en)
|
1994-11-14 |
1998-08-06 |
The Ludwig Institute For Cancer Research |
Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
|
US6245530B1
(en)
|
1995-08-01 |
2001-06-12 |
Ludwig Institute For Cancer Research |
Receptor ligand
|
US5792453A
(en)
|
1995-02-28 |
1998-08-11 |
The Regents Of The University Of California |
Gene transfer-mediated angiogenesis therapy
|
US5707618A
(en)
|
1995-03-24 |
1998-01-13 |
Genzyme Corporation |
Adenovirus vectors for gene therapy
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
FR2732357B1
(fr)
|
1995-03-31 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
|
US5869079A
(en)
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
US5773289A
(en)
|
1995-06-06 |
1998-06-30 |
University Of Pittsburgh |
AAV directed targeted integration
|
US6699843B2
(en)
|
1995-06-07 |
2004-03-02 |
Gilead Sciences, Inc. |
Method for treatment of tumors using nucleic acid ligands to PDGF
|
US6361946B1
(en)
|
1997-02-05 |
2002-03-26 |
Licentia Ltd |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
US5622856A
(en)
|
1995-08-03 |
1997-04-22 |
Avigen |
High efficiency helper system for AAV vector production
|
US5730977A
(en)
|
1995-08-21 |
1998-03-24 |
Mitsui Toatsu Chemicals, Inc. |
Anti-VEGF human monoclonal antibody
|
EP1382679A3
(en)
|
1995-09-08 |
2004-11-10 |
Genentech, Inc. |
Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists
|
EP1553182B1
(en)
|
1995-09-29 |
2010-03-03 |
Universita Degli Studi Di Siena |
Regulated genes and uses thereof
|
US5830727A
(en)
|
1995-11-18 |
1998-11-03 |
Human Gene Therapy Research Institute |
Herpes simplex virus amplicon mini-vector gene transfer system
|
PL187400B1
(pl)
|
1996-02-20 |
2004-06-30 |
Applied Research Systems |
Białka hybrydowe tworzące heterodimery
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
DE69740038D1
(hu)
|
1996-07-12 |
2010-12-16 |
Genentech Inc |
|
US6828426B1
(en)
|
1996-07-15 |
2004-12-07 |
Chugai Seiyaku Kabushiki Kaisha |
VEGF-like factor
|
US6423512B1
(en)
|
1996-07-26 |
2002-07-23 |
Novartis Ag |
Fusion polypeptides
|
DK0956339T3
(da)
|
1996-08-23 |
2006-01-30 |
Licentia Oy |
Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
|
JP2001501471A
(ja)
|
1996-09-24 |
2001-02-06 |
メルク エンド カンパニー インコーポレーテッド |
血管新生の阻害のための遺伝子治療
|
US6051698A
(en)
|
1997-06-06 |
2000-04-18 |
Janjic; Nebojsa |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
CA2274675A1
(en)
|
1996-12-20 |
1998-07-02 |
Ludwig Institute For Cancer Research |
Vegf-b/receptor complex and uses thereof
|
US7125714B2
(en)
|
1997-02-05 |
2006-10-24 |
Licentia Ltd. |
Progenitor cell materials and methods
|
AU743758B2
(en)
|
1997-04-07 |
2002-02-07 |
Genentech Inc. |
Anti-VEGF antibodies
|
DE69839529D1
(de)
|
1997-12-24 |
2008-07-03 |
Ludwig Inst Cancer Res |
Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
|
EP1088084B1
(en)
|
1998-06-15 |
2006-09-13 |
GTC Biotherapeutics, Inc. |
Erythropoietin analog-human serum albumin fusion protein
|
US20020164687A1
(en)
|
1998-09-30 |
2002-11-07 |
Ulf Eriksson |
Platelet-derived growth factor C, DNA coding therefor, and uses thereof
|
CA2345276C
(en)
|
1998-10-09 |
2011-03-29 |
Ludwig Institute For Cancer Research |
Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy
|
EP1124570A4
(en)
|
1998-10-19 |
2005-03-30 |
Ludwig Inst Cancer Res |
NOVEL NEUROPILIN BINDING / GROWTH FACTOR AND APPLICATIONS THEREOF
|
EP1126863B1
(en)
|
1998-11-02 |
2006-05-03 |
Ludwig Institute For Cancer Research |
Vascular endothelial growth factor-like protein from orf virus nz10 binds and activates mammalian vegf receptor-2
|
US7148037B2
(en)
|
1998-11-10 |
2006-12-12 |
Ludwig Institute For Cancer Research |
Platelet-derived growth factor D, DNA coding therefor, and uses thereof
|
CN1330555A
(zh)
|
1998-12-21 |
2002-01-09 |
路德维格癌症研究所 |
抗截短的vegf-d的抗体及其应用
|
JP2000191337A
(ja)
|
1998-12-25 |
2000-07-11 |
Furukawa Electric Co Ltd:The |
フ―ド付きガラス微粒子合成用ト―チ
|
US20020064528A1
(en)
|
2000-01-28 |
2002-05-30 |
Zhenping Zhu |
Antibodies specific to KDR and uses thereof
|
CA2361615A1
(en)
|
1999-02-08 |
2000-08-10 |
Human Genome Sciences, Inc. |
The use of vascular endothelial growth factor 2 antagonist in the treatment of an injury to or disorder of an eye
|
JP4926320B2
(ja)
|
1999-04-28 |
2012-05-09 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
Vegfの選択的阻害による癌処置のための組成物および方法
|
EP1180121B9
(en)
|
1999-05-17 |
2004-09-08 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
EP1544299B1
(en)
|
1999-06-08 |
2008-12-17 |
Regeneron Pharmaceuticals, Inc. |
VEGF receptor chimeras for the treatment of eye disorders characterized by vascular permeability
|
EP1194539A2
(en)
|
1999-06-25 |
2002-04-10 |
Universität Zürich |
Hetero-associating coiled-coil peptides and screening method therefor
|
JP4944324B2
(ja)
|
1999-07-13 |
2012-05-30 |
ボルダー バイオテクノロジー, インコーポレイテッド |
免疫グロブリン融合タンパク質
|
WO2001012669A1
(en)
|
1999-08-16 |
2001-02-22 |
Universita' Degli Studi Di Siena |
Vegf-d and angiogenic use thereof
|
WO2001028472A1
(en)
|
1999-10-21 |
2001-04-26 |
Alcon Universal Ltd. |
Drug delivery device
|
AU783683B2
(en)
|
2000-01-18 |
2005-11-24 |
Vegenics Limited |
VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
|
DE60131146T2
(de)
|
2000-02-25 |
2008-03-06 |
Ludwig Institute For Cancer Research |
Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
|
WO2001064235A1
(en)
|
2000-03-02 |
2001-09-07 |
Ludwig Institute For Cancer Research |
Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d
|
US20020102260A1
(en)
|
2000-03-02 |
2002-08-01 |
Marc Achen |
Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
|
AU6456501A
(en)
|
2000-05-03 |
2001-11-12 |
Ludwig Inst Cancer Res |
A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
|
NZ518077A
(en)
|
2000-08-04 |
2003-11-28 |
Human Genome Sciences Inc |
Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
|
WO2002029087A2
(en)
|
2000-10-02 |
2002-04-11 |
St. Elizabeth's Medical Center Of Boston, Inc. |
Use of lymphangiogenic agents to treat lymphatic disorders
|
US20020197691A1
(en)
|
2001-04-30 |
2002-12-26 |
Myriad Genetics, Incorporated |
FLT4-interacting proteins and use thereof
|
US20030211988A1
(en)
|
2001-01-09 |
2003-11-13 |
Epstein Stephen E |
Enhancing lymph channel development and treatment of lymphatic obstructive disease
|
US7611711B2
(en)
|
2001-01-17 |
2009-11-03 |
Vegenics Limited |
VEGFR-3 inhibitor materials and methods
|
JP4669984B2
(ja)
|
2001-01-19 |
2011-04-13 |
ベジェニクス リミテッド |
腫瘍画像化のターゲットとしてのF1t4(VEGFR−3)および抗腫瘍療法
|
US20030176674A1
(en)
|
2001-04-13 |
2003-09-18 |
Rosen Craig A. |
Vascular endothelial growth factor 2
|
AU2002257142B2
(en)
|
2001-04-13 |
2008-09-04 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
AU2002256172A1
(en)
|
2001-04-13 |
2002-10-28 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
EP1427750B1
(en)
|
2001-08-30 |
2010-12-08 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins
|
US20030180294A1
(en)
|
2002-02-22 |
2003-09-25 |
Devries Gerald W. |
Methods of extending corneal graft survival
|
PT1916001E
(pt)
|
2002-03-04 |
2011-07-18 |
Imclone Llc |
Anticorpos humanos específicos para kdr e suas utilizações
|
US20030232437A1
(en)
|
2002-06-17 |
2003-12-18 |
Isis Pharmaceuticals Inc. |
Antisense modulation of VEGF-C expression
|
US20030228283A1
(en)
|
2002-05-03 |
2003-12-11 |
Ludwig Institute For Cancer Research |
Preventing secondary lymphedema with VEGF-D DNA
|
US20070184089A1
(en)
|
2002-07-15 |
2007-08-09 |
Alcon, Inc. |
Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
|
WO2004009773A2
(en)
|
2002-07-23 |
2004-01-29 |
Ludwig Institute For Cancer Research |
Methods and compositions for activating or inhibiting vegf-d and vegf-c
|
US20040023390A1
(en)
|
2002-08-05 |
2004-02-05 |
Davidson Beverly L. |
SiRNA-mediated gene silencing with viral vectors
|
AU2003293351A1
(en)
|
2002-08-14 |
2004-03-19 |
Avidis Sa |
Production of multimeric fusion proteins using a c4bp scaffold
|
DE60329116D1
(de)
|
2002-10-11 |
2009-10-15 |
Zymogenetics Inc |
Herstellung von homotrimeren fusionsproteinen
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
WO2004106378A2
(en)
|
2003-05-28 |
2004-12-09 |
Regeneron Pharmaceuticals, Inc. |
Method of treating corneal transplant rejection by using vegf antagonists
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
AU2005222384A1
(en)
|
2004-03-05 |
2005-09-22 |
Vegenics Limited |
Growth factor binding constructs materials and methods
|
US8529927B2
(en)
|
2004-04-30 |
2013-09-10 |
Allergan, Inc. |
Alpha-2 agonist polymeric drug delivery systems
|
US20050244471A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
US20050244462A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
US20050244500A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intravitreal implants in conjuction with photodynamic therapy to improve vision
|
MXPA06014421A
(es)
|
2004-06-10 |
2007-05-04 |
Regeneron Pharma |
Uso de inhibidores de vegf para el tratamiento de cancer humano.
|
US20060110364A1
(en)
*
|
2004-08-20 |
2006-05-25 |
Ludwig Institute For Cancer Research |
Vector-mediated delivery of polynucleotides encoding soluble VEGF receptors
|
WO2006088650A2
(en)
|
2005-02-02 |
2006-08-24 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a vegf inhibitor
|
AU2006223314A1
(en)
|
2005-03-11 |
2006-09-21 |
Regeneron Pharmaceuticals, Inc. |
Treating anemia by inhibition of VEGF
|
WO2007096398A1
(en)
|
2006-02-22 |
2007-08-30 |
University Of Zurich |
Soluble receptors and methods for treating autoimmune or demyelinating diseases
|
JP5216002B2
(ja)
|
2006-06-16 |
2013-06-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
硝子体内投与に適したvegfアンタゴニスト製剤
|
JP5323720B2
(ja)
|
2006-12-18 |
2013-10-23 |
アルコン リサーチ, リミテッド |
眼用薬物送達のためのデバイスおよび方法
|
JP2011500086A
(ja)
|
2007-10-22 |
2011-01-06 |
シェーリング コーポレイション |
完全ヒト抗vegf抗体および使用方法
|
WO2009060198A1
(en)
|
2007-11-09 |
2009-05-14 |
Peregrine Pharmaceuticals, Inc. |
Anti-vegf antibody compositions and methods
|
US8234784B2
(en)
|
2008-02-13 |
2012-08-07 |
Younger Steven W |
Valve piston repositioning apparatus and method
|
EP2259795B1
(en)
|
2008-03-26 |
2016-04-06 |
Epitomics, Inc. |
Anti-vegf antibody
|
CA3020290A1
(en)
|
2008-06-25 |
2009-12-30 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Stable and soluble antibodies inhibiting vegf
|
EP2361095B1
(en)
|
2008-11-25 |
2017-12-20 |
AlderBio Holdings LLC |
Antagonists of il-6 to raise albumin and/or lower crp
|
KR101093717B1
(ko)
|
2008-11-26 |
2011-12-19 |
한국생명공학연구원 |
Vegf―특이적인 인간항체
|
WO2010127029A1
(en)
|
2009-05-01 |
2010-11-04 |
Ophthotech Corporation |
Methods for treating or preventing ophthalmological diseases
|
PT2846836T
(pt)
*
|
2012-05-07 |
2019-10-29 |
Allergan Inc |
Método de tratamento de dmi em doentes refratários à terapia anti-vegf
|
EP3693381A1
(en)
*
|
2013-02-18 |
2020-08-12 |
Vegenics Pty Limited |
Ligand binding molecules and uses thereof
|
US10274503B2
(en)
*
|
2013-05-08 |
2019-04-30 |
Vegenics Pty Limited |
Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
|